中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.017 seconds)

    FUSION PROTEINS
    1.
    发明申请
    FUSION PROTEINS 有权
    融合蛋白

    公开(公告)号：US20130115682A1

    公开(公告)日：2013-05-09

    申请号：US13738235

    申请日：2013-01-10

    Applicant: SYNTAXIN, LIMITED

    Inventor： Keith Alan FOSTER ,  John CHADDOCK ,  Philip MARKS ,  Patrick STANCOMBE ,  Lyndsey DUROSE

    IPC: C12N9/50

    CPC classification number: C12N9/50 ,  A61K38/00 ,  C07K14/33 ,  C07K2319/06 ,  C07K2319/50 ,  C12N15/62

    Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.

    Abstract translation: 本发明提供了一种单链多肽融合蛋白，其包含：非细胞毒性蛋白酶或其片段，所述蛋白酶或蛋白酶片段能够切割靶细胞的胞外融合装置的蛋白质; 能够结合靶细胞上的结合位点的靶向物质，所述结合位点能够经历内吞作用以掺入靶细胞内的内皮细胞; 蛋白酶切割位点，其中融合蛋白可被蛋白酶切割，其中蛋白酶切割位点位于非细胞毒性蛋白酶或其片段与靶向部位之间; 以及能够将位于内体内的蛋白酶或蛋白酶片段穿过体内膜并进入靶细胞的胞质溶胶的易位结构域。

    Carrier for targeting nerve cells
    2.
    发明授权
    Carrier for targeting nerve cells 有权
    用于靶向神经细胞的载体

    公开(公告)号：US09115350B2

    公开(公告)日：2015-08-25

    申请号：US13867740

    申请日：2013-04-22

    Applicant: Syntaxin Limited

    Inventor： Andreas Rummel ,  Tanja Weil ,  Aleksandrs Gutcaits

    IPC: A61K39/08 ,  A61K38/48 ,  C12N9/52 ,  C07K14/33 ,  A61K38/00

    CPC classification number: C12N9/52 ,  A61K38/00 ,  C07K14/33 ,  C12Y304/24069 ,  Y02A50/469 ,  Y02A50/473

    Abstract: The present invention relates to a transport protein which can be obtained by modifying the heavy chain of the neurotoxin formed by Clostridium botulinum wherein (i) the protein binds specifically to nerve cells with a higher or lower affinity as the native neurotoxin; (ii) the protein has an increased or reduced neurotoxicity compared to the native neurotoxin, the neurotoxicity being preferably determined in the hemidiaphragm assay; and/or (iii) the protein comprises a lower affinity against neutralizing antibodies compared to the native neurotoxin. The invention also relates to methods for producing the same and the use thereof in cosmetic and pharmaceutical compositions.

    Abstract translation: 本发明涉及通过改变由肉毒梭菌形成的神经毒素的重链而获得的转运蛋白，其中（i）所述蛋白质以与天然神经毒素更高或更低的亲和力的神经细胞特异性结合; （ii）与天然神经毒素相比，蛋白质具有增加或减少的神经毒性，神经毒性优选在膈膜测定中确定; 和/或（iii）与天然神经毒素相比，蛋白质包含对中和抗体的较低亲和力。 本发明还涉及其制备方法及其在化妆品和药物组合物中的用途。

    INHIBITION OF SECRETION FROM NON-NEURONAL CELLS
    3.
    发明申请
    INHIBITION OF SECRETION FROM NON-NEURONAL CELLS 审中-公开
    从非神经细胞抑制分泌

    公开(公告)号：US20140348828A1

    公开(公告)日：2014-11-27

    申请号：US14459955

    申请日：2014-08-14

    Applicant: Syntaxin, Limited

    Inventor： Keith Alan FOSTER ,  John Andrew CHADDOCK ,  Conrad Padraig QUINN ,  John Robert PURKISS

    IPC: C12N9/52

    CPC classification number: C12N9/52 ,  A61K38/1808 ,  A61K38/4886 ,  A61K47/64 ,  C07K16/1282 ,  C07K2319/00 ,  C12Y304/24069

    Abstract: The present invention relates to treatment of disease by inhibition of cellular secretory processes, to agents and compositions therefor, and to manufacture of those agents and compositions. The present invention relates particularly, to treatment of disease dependent upon the exocytotic activity of endocrine cells, exocrine cells, inflammatory cells, cells of the immune system, cells of the cardiovascular system and bone cells.

    Abstract translation: 本发明涉及通过抑制细胞分泌过程，其药剂及其组合物治疗疾病，以及制备这些药剂和组合物。 本发明特别涉及依赖于内分泌细胞，外分泌细胞，炎症细胞，免疫系统细胞，心血管系统细胞和骨细胞的胞吐活性的疾病的治疗。

    Assay for assessment of endosomal transport
    5.
    发明授权
    Assay for assessment of endosomal transport 有权
    用于评估体内运输的测定

    公开(公告)号：US09170252B2

    公开(公告)日：2015-10-27

    申请号：US14429668

    申请日：2013-10-23

    Applicant: SYNTAXIN LIMITED

    Inventor： Elaine Harper

    IPC: G01N33/53 ,  G01N31/00 ,  G01N33/50

    CPC classification number: G01N33/502 ,  G01N33/5008 ,  G01N33/5076 ,  G01N2333/952

    Abstract: The invention provides an assay and corresponding kit for assessing the delivery efficiency of a molecule into a eukaryotic cell (basic assay). The present invention also provides an assay and corresponding kit for assessing the inhibitory effect of a test molecule in relation to the before-mentioned basic assay.

    Abstract translation: 本发明提供了用于评估分子进入真核细胞的递送效率的测定和相应试剂盒（碱性测定）。 本发明还提供了用于评估测试分子相对于前述碱性测定的抑制作用的测定和相应试剂盒。

    ASSAY FOR ASSESSMENT OF ENDOSOMAL TRANSPORT
    6.
    发明申请
    ASSAY FOR ASSESSMENT OF ENDOSOMAL TRANSPORT 有权
    内分泌运输评估测定

    公开(公告)号：US20150241408A1

    公开(公告)日：2015-08-27

    申请号：US14429668

    申请日：2013-10-23

    Applicant: SYNTAXIN LIMITED

    Inventor： Elaine Harper

    IPC: G01N33/50

    CPC classification number: G01N33/502 ,  G01N33/5008 ,  G01N33/5076 ,  G01N2333/952

    Abstract: The invention provides an assay and corresponding kit for assessing the delivery efficiency of a molecule into a eukaryotic cell (basic assay). The present invention also provides an assay and corresponding kit for assessing the inhibitory effect of a test molecule in relation to the before-mentioned basic assay.

    Abstract translation: 本发明提供了用于评估分子进入真核细胞的递送效率的测定和相应试剂盒（碱性测定）。 本发明还提供了用于评估测试分子相对于前述碱性测定的抑制作用的测定和相应试剂盒。

    Fusion proteins
    7.
    发明授权
    Fusion proteins 有权
    融合蛋白

    公开(公告)号：US08956847B2

    公开(公告)日：2015-02-17

    申请号：US13738235

    申请日：2013-01-10

    Applicant: Syntaxin, Limited

    Inventor： Keith Alan Foster ,  John Chaddock ,  Philip Marks ,  Patrick Stancombe ,  Lyndsey Durose

    IPC: C12N9/50 ,  C07K14/33 ,  C12N15/62 ,  A61K38/00

    CPC classification number: C12N9/50 ,  A61K38/00 ,  C07K14/33 ,  C07K2319/06 ,  C07K2319/50 ,  C12N15/62

    Abstract: The invention provides a single chain, polypeptide fusion protein, comprising: a non-cytotoxic protease, or a fragment thereof, which protease or protease fragment is capable of cleaving a protein of the exocytic fusion apparatus of a target cell; a Targeting Moiety that is capable of binding to a Binding Site on the target cell, which Binding Site is capable of undergoing endocytosis to be incorporated into an endocome within the target cell; a protease cleaving site at which site the fusion protein is cleavable by the protease, wherein the protease cleavage site is located between the non-cytotoxic protease or fragment thereof and the Targeting Moiety; and the translocation domain that is capable of translocating the protease or protease fragment from within an endosome, across the endosomal membrane and into the cytosol of the target cell.

    Abstract translation: 本发明提供了一种单链多肽融合蛋白，其包含：非细胞毒性蛋白酶或其片段，所述蛋白酶或蛋白酶片段能够切割靶细胞的胞外融合装置的蛋白质; 能够结合靶细胞上的结合位点的靶向物质，所述结合位点能够经历内吞作用以掺入靶细胞内的内皮细胞; 蛋白酶切割位点，其中融合蛋白可被蛋白酶切割，其中蛋白酶切割位点位于非细胞毒性蛋白酶或其片段与靶向部位之间; 以及能够将位于内体内的蛋白酶或蛋白酶片段穿过体内膜并进入靶细胞的胞质溶胶的易位结构域。

    RECOMBINANT CLOSTRIDIUM BOTULINUM NEUROTOXINS
    9.
    发明申请
    RECOMBINANT CLOSTRIDIUM BOTULINUM NEUROTOXINS 有权
    重组胶原蛋白神经毒素

    公开(公告)号：US20150247139A1

    公开(公告)日：2015-09-03

    申请号：US14427234

    申请日：2013-10-31

    Applicant: SYNTAXIN LIMITED ,  IPSEN BIOPHARM LIMITED

    Inventor： Aimee Cossins ,  Matthew Beard

    IPC: C12N9/52

    CPC classification number: C12N9/52 ,  A61K38/00 ,  C12Y304/24069 ,  Y02A50/469

    Abstract: The invention provides a nucleic acid sequence comprising a sequence of contiguous nucleotides, wherein said sequence of contiguous nucleotides has at least 90% sequence identity to the nucleic acid sequence of SEQ ID NO: 1, and wherein said sequence of contiguous nucleotides encodes a single-chain BoNT/E1 protein. The present invention also provides methods for producing soluble single-chain BoNT/E1 protein in an E. coli host cell, together with methods for producing soluble di-chain BoNT/E1 protein.

    Abstract translation: 本发明提供了包含连续核苷酸序列的核酸序列，其中所述连续核苷酸序列与SEQ ID NO：1的核酸序列具有至少90％的序列同一性，并且其中所述连续核苷酸序列编码单链核苷酸序列， 链BoNT / E1蛋白。 本发明还提供了在大肠杆菌宿主细胞中生产可溶性单链BoNT / E1蛋白的方法，以及生产可溶性双链BoNT / E1蛋白的方法。

Patent Agency Ranking